None
Quote | IDEAYA Biosciences Inc. (NYSE:IDYA)
Last: | $ |
---|---|
Change Percent: | 1.34% |
Open: | $6.60 |
Close: | $6.82 |
High: | $6.95 |
Low: | $6.60 |
Volume: | 34,610 |
Last Trade Date Time: | 02/12/2020 04:41:43 pm |
News | IDEAYA Biosciences Inc. (NYSE:IDYA)
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
Message Board Posts | IDEAYA Biosciences Inc. (NYSE:IDYA)
Subject | By | Source | When |
---|---|---|---|
$THER STOCK CANCER GOOD NEWS | Jayzp | investorshub | 04/24/2023 12:39:39 PM |
Finally some pub. Just take something to | Poshfox | investorshub | 09/02/2020 10:49:52 PM |
$60 million becomes $100 offering. | Laster | investorshub | 06/18/2020 2:07:55 AM |
POS company gets $100 million and then announces | Laster | investorshub | 06/17/2020 12:26:28 AM |
Awesome press release, lets see where this goes | dinogreeves | investorshub | 06/16/2020 12:19:43 PM |
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...